Drug Profile
Ranibizumab - Genentech/Novartis Ophthalmics
Alternative Names: ACCENTRIX; AMD Fab; Anti-VEGF fragment; Lucentis; Rabinismab; RG-3645; RG-6321; rhuFab V2; rhuFab V2 AMD; Susvimo; SusvimoTM; VEGF antibody fragmentLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Genentech; Novartis Ophthalmics; Roche
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Diabetic retinopathy; Retinal oedema; Retinopathy of prematurity; Wet age-related macular degeneration
- Phase I/II Polypoidal choroidal vasculopathy
- Discontinued Retinal telangiectasis
Most Recent Events
- 01 Feb 2024 Chugai Pharmaceutical plans regulatory filing for Diabetic macular oedema and Wet-age-related macular degeneration in Japan (Intraocular, Implant) in 2025 (Chugai pharmaceutical pipeline, February 2024)
- 18 Jan 2024 Hoffmann-La Roche withdraws the phase III Diagrid trial in Wet age-related macular degeneration in United Kingdom, United Arab Emirates, Argentina, Austria, Brazil, Canada, Chile, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Multinational, Netherlands, Norway, Poland, Portugal, Singapore, Spain, Switzerland and Thailand (Intraocular) because Roche/Genentech initiated an immediate pause of all new PDS implantations (NCT05126966) (EudraCT2021-003226-71 )
- 23 Aug 2023 Chugai Pharmaceutical plans regulatory filing for Wet age related macular degeneration in or after 2026 (Roche pipeline, August 2023)